| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_105f5a3002f31ca7e28956e60a952c80 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2005-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2006-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a10545d6e9c4dd06b14f2dbe920e834
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eefe0f073e6e57ccf629bb31680d581e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_790c917ff8cfd6de5ad8a9c6e015bccb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e510d483f3c7a3d8fbd033ad5dd3c2b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c8c9168dd66839bc311e2b6afcac752
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a658424851f2e60bc5fdc0fcded484c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9edb43619e79bd1eb3a4cf49381446e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a209c8fa080b32a3647e34c89ace122c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c60ca3d8d0d6a044cd99d091b359ec87 |
| publicationDate |
2006-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2287576-C1 |
| titleOfInvention |
HUMAN MELANOMA CELLULAR LINE mel Ibr USED IN PREPARING ANTITUMOR VACCINE |
| abstract |
FIELD: biotechnology, medicine, oncology. n SUBSTANCE: invention relates to a novel human melanoma cellular line mel Ibr possessing stable cultural and morphological indices that is stored in the Specialized collection of cellular cultures in Cytology institute RAS at number PKKK (P) 689D. The cellular line is characterized by expression of melanoma (differentiating) markers - CD-63, HMW and cancer-testicular marker MAGE-3, the presence of histo-compatibility antigens of the first and the second class. The cellular line can be used in creature of antitumor (all-cellular, genetic engineering) vaccines used in treatment of melanoma and other malignant neoplasms. Using this cellular line provides preparing the novel effective antitumor vaccine. Invention can be used in medicine for vaccine therapy of malignant neoplasms. n EFFECT: valuable medicinal properties of cellular line. n 1 tbl, 2 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2724503-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2608959-C1 |
| priorityDate |
2005-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |